Gunderson Dettmer represented TCG Crossover in its inaugural $824 million fund.  TCG Crossover invests in innovative drug discovery companies that are seeking to make an impact on unmet medical needs.  In connection with its relationship with The Column Group, TCG Crossover adds extensive scientific and operating expertise to its portfolio companies.

The Gunderson team consisted of Andrew Thornborrow, Tony Huynh, Jason Li and David Eberle